Association of a single nucleotide polymorphic variation in the human chromosome 19q13.3 with drug responses in the NCI60 cell lines

K.K. Nissen, Ulla Birgitte Vogel, B.A. Nexo

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

We studied the importance of certain polymorphisms on human chromosome 19q13.3 for drug sensitivity in human tumor cell cultures. NCI60 is a panel of 60 established tumor-derived cell lines, which have been tested for their sensitivity to tens of thousands of different drugs. Here we investigate the correlations between the responses of the NCI60 cells to different anticancer drugs and their respective alleles of five DNA polymorphisms located in a cancer-related chromosomal area. One polymorphism, located in the 5' noncoding region of the gene ASE-1, alias CD3EAP, proved to be associated with drug sensitivity (P=0.025). The same polymorphism has previously been associated with treatment response of multiple myeloma after bone marrow ablation. The polymorphism ASE-1-e1 was of importance for the drug response in the human cancer cell lines investigated and could eventually become important for individualized drug treatment in humans. Anti-Cancer Drugs 20:174-178
Original languageEnglish
JournalAnti-Cancer Drugs
Volume20
Issue number3
Pages (from-to)174-178
ISSN0959-4973
DOIs
Publication statusPublished - 2009

Keywords

  • CD3EAP
  • single nucleotide polymorphisms
  • NCI60
  • ASE-1
  • human chromosome 19q13.3

Cite this